Xarelto



Indications and Reactions:

Role Indications Reactions
Primary
Atrial Fibrillation 23.0%
Product Used For Unknown Indication 18.7%
Cerebrovascular Accident Prophylaxis 18.3%
Thrombosis Prophylaxis 10.7%
Deep Vein Thrombosis 4.9%
Knee Arthroplasty 4.3%
Hypertension 3.6%
Pulmonary Embolism 2.4%
Hip Arthroplasty 2.3%
Embolism Venous 2.2%
Ill-defined Disorder 1.4%
Pain 1.3%
Blood Pressure 1.1%
Cardiac Disorder 1.1%
Thrombosis 1.1%
Anticoagulant Therapy 0.9%
Diabetes Mellitus 0.7%
Prophylaxis 0.7%
Orthopedic Procedure 0.7%
Knee Operation 0.6%
Pulmonary Embolism 23.2%
Deep Vein Thrombosis 11.8%
Thrombosis 7.4%
Cerebrovascular Accident 6.8%
Gastrointestinal Haemorrhage 6.7%
Haemorrhage 5.5%
Haemorrhage Intracranial 4.8%
Haemoglobin Decreased 4.1%
Drug Ineffective 3.8%
Death 3.0%
Ischaemic Stroke 2.8%
Thrombocytopenia 2.6%
Transient Ischaemic Attack 2.5%
Haematoma 2.4%
International Normalised Ratio Increased 2.3%
Rectal Haemorrhage 2.2%
Subdural Haematoma 2.0%
Cerebral Haemorrhage 2.0%
Renal Impairment 2.0%
Vomiting 2.0%
Secondary
Atrial Fibrillation 26.6%
Cerebrovascular Accident Prophylaxis 23.6%
Product Used For Unknown Indication 10.6%
Thrombosis Prophylaxis 10.1%
Deep Vein Thrombosis 5.1%
Knee Arthroplasty 4.3%
Embolism Venous 3.7%
Hypertension 3.3%
Pulmonary Embolism 2.6%
Hip Arthroplasty 2.1%
Pain 1.4%
Thrombosis 1.3%
Blood Pressure 1.0%
Cardiac Disorder 0.8%
Anticoagulant Therapy 0.7%
Prophylaxis 0.7%
Diabetes Mellitus 0.6%
Cerebrovascular Accident 0.5%
Blood Cholesterol 0.5%
Cardiac Failure 0.5%
Pulmonary Embolism 20.2%
Deep Vein Thrombosis 11.2%
Thrombosis 7.5%
Gastrointestinal Haemorrhage 6.7%
Drug Ineffective 6.4%
Cerebrovascular Accident 5.6%
Haemoglobin Decreased 4.3%
Haemorrhage Intracranial 3.9%
Renal Impairment 3.6%
Thrombocytopenia 3.4%
Ischaemic Stroke 3.3%
Haemorrhage 3.2%
Haematoma 3.1%
Transient Ischaemic Attack 3.0%
Rectal Haemorrhage 2.6%
Subdural Haematoma 2.5%
Melaena 2.4%
Renal Failure Acute 2.4%
Vomiting 2.4%
International Normalised Ratio Increased 2.2%
Concomitant
Product Used For Unknown Indication 45.1%
Atrial Fibrillation 10.2%
Hypertension 8.5%
Rheumatoid Arthritis 4.6%
Pain 3.7%
Anticoagulant Therapy 3.1%
Diabetes Mellitus 2.4%
Prophylaxis 2.3%
Cardiac Disorder 2.2%
Thrombosis Prophylaxis 2.2%
Cardiac Failure 2.1%
Blood Cholesterol Increased 2.0%
Pulmonary Embolism 1.9%
Deep Vein Thrombosis 1.6%
Depression 1.5%
Asthma 1.4%
Cardiac Failure Chronic 1.4%
Chronic Obstructive Pulmonary Disease 1.4%
Arrhythmia 1.3%
Plasma Cell Myeloma 1.2%
Vomiting 9.2%
Thrombosis 7.9%
Renal Failure Acute 7.2%
Weight Decreased 7.2%
Death 5.9%
Pneumonia 5.9%
Hepatitis Acute 5.3%
Nausea 5.3%
Syncope 5.3%
Atrial Fibrillation 4.6%
Pain 4.6%
Pulmonary Embolism 3.9%
Tremor 3.9%
Weight Increased 3.9%
Headache 3.3%
Oedema Peripheral 3.3%
Off Label Use 3.3%
Pruritus 3.3%
Tachycardia 3.3%
Wrist Deformity 3.3%
Interacting
Atrial Fibrillation 23.7%
Cerebrovascular Accident Prophylaxis 23.3%
Product Used For Unknown Indication 17.0%
Thrombosis Prophylaxis 5.8%
Hypertension 3.8%
Cardiac Disorder 3.4%
Pain 2.5%
Blood Pressure Abnormal 2.4%
Hip Arthroplasty 2.1%
Prophylaxis 2.0%
Anticoagulant Therapy 1.7%
Antiplatelet Therapy 1.5%
Knee Arthroplasty 1.5%
Diuretic Therapy 1.5%
Coronary Artery Disease 1.4%
Diabetes Mellitus 1.4%
Ill-defined Disorder 1.4%
Blood Cholesterol Abnormal 1.3%
Atrial Flutter 1.2%
Stent Placement 1.2%
Gastrointestinal Haemorrhage 16.3%
Haemorrhage 12.4%
Rectal Haemorrhage 6.9%
Product Quality Issue 5.9%
Haemoglobin Decreased 5.4%
Haematochezia 5.0%
Haematuria 4.5%
Haemorrhage Intracranial 4.5%
International Normalised Ratio Increased 4.5%
Melaena 4.5%
Subdural Haematoma 4.0%
Blood Urine Present 3.5%
Drug Interaction 3.0%
Inappropriate Schedule Of Drug Administration 3.0%
Occult Blood Positive 3.0%
Prothrombin Time Prolonged 3.0%
Upper Gastrointestinal Haemorrhage 3.0%
Vaginal Haemorrhage 3.0%
Epistaxis 2.5%
Haemoptysis 2.5%